Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 63INDUSTRY 11OTHER_GOV 5NIH 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 196Neoplasms 104Colorectal Neoplasms 91Stomach Neoplasms 80Uterine Cervical Neoplasms 70Carcinoma, Non-Small-Cell Lung 67Carcinoma, Hepatocellular 53Lung Neoplasms 48Prostatic Neoplasms 47Rectal Neoplasms 46Esophageal Neoplasms 39Pancreatic Neoplasms 37Colonic Neoplasms 36Ovarian Neoplasms 35Recurrence 33Head and Neck Neoplasms 33Neoplasm Metastasis 28Motor Activity 28Multiple Myeloma 27Small Cell Lung Carcinoma 26Melanoma 25Polycystic Ovary Syndrome 24Lymphoma, Non-Hodgkin 24Lymphoma 24Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Pain 20Brain Neoplasms 20Nasopharyngeal Carcinoma 18Hematologic Neoplasms 17

Interventions

pertuzumab 2Trastuzumab 2Docetaxel 2Carboplatin 2Epirubicin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Pathologic Complete Response × Clear all
NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
610 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
71 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT01830244 2017-07-02

Neonab

Barwon Health

Phase 2 Unknown
60 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡